ストックスクリーナーアプリを入手
150.49
3.28%
4.785
前日終値:
$145.70
開ける：
$146.36
24時間の取引高:
246.44K
Relative Volume:
0.68
時価総額：
$4.36B
収益：
$290.51M
当期純損益:
$89.16M
株価収益率:
50.33
EPS:
2.99
ネットキャッシュフロー:
$119.18M
1週間 パフォーマンス:
+0.14%
1か月 パフォーマンス:
-0.93%
6か月 パフォーマンス:
-19.90%
1年 パフォーマンス:
-23.81%
1日の値動き範囲:
$145.63
$152.04
1週間の範囲:
$142.51
$152.04
52週間の値動き範囲:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
KRYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
150.49 | 4.23B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 開始されました | Jefferies | Buy |
| 2024-08-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN
RSI + MACD Show Convergence for Krystal Biotech Inc.July 2025 Selloffs & Daily Chart Pattern Signals - newsyoung.net
AI Trend Models Suggest Bounce for Krystal Biotech Inc.July 2025 Opening Moves & High Accuracy Investment Entry Signals - newsimpact.co.kr
Can Krystal Biotech Inc. keep up with sector leadersTrade Analysis Summary & Consistent Return Investment Signals - mustnews.co.kr
Local biotech co-founder named to Forbes 50 Over 50 - MSN
What are Krystal Biotech Inc.’s growth leversSwing Trade & Low Risk Investment Opportunities - thegnnews.com
Krystal Biotech Inc. Matches Institutional Buying FilterWatch List & Stock Timing and Entry Methods - newsimpact.co.kr
Why Krystal Biotech Inc. stock attracts strong analyst attentionMarket Movers & Technical Buy Zone Confirmations - sundaytimes.kr
Support Zone Holds Steady for Krystal Biotech Inc. After Dip2025 EndofYear Setup & Real-Time Buy Signal Notifications - beatles.ru
Evercore ISI Maintains Buy Rating on Krystal Biotech with $200 Target - AInvest
Evercore Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛
Astrana Health And 2 Insider Favorites For High Growth - simplywall.st
Krystal Biotech, Inc. (NASDAQ:KRYS) Q2 2025 Earnings Call Transcript - MSN
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth - MSN
Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. - Barchart.com
Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings - AInvest
Krystal Biotech Q2 Earnings Call: Strong Growth Amid Challenges - AInvest
Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations - MSN
Krystal Biotech: Citigroup maintains Neutral, PT down to $166 from $176. - AInvest
Reassessing Krystal Biotech: Navigating Short-Term Volatility to Unlock Long-Term Value - AInvest
Krystal Biotech price target lowered to $182 from $192 at BofA - Yahoo Finance
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $166 to $240 - 富途牛牛
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook - Nasdaq
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q2 2025 Results - TipRanks
Krystal Biotech price target lowered to $166 from $176 at Citi - TipRanks
Krystal Biotech stock price target lowered to $182 at BofA on growth concerns - Investing.com Nigeria
Krystal Biotech Grows Revenue On VYJUVEK’s Expanding Global Reach - Finimize
Krystal Biotech Plummets 14.04% on Record $290M Trading Volume Ranks 382nd Amid Surging Revenue and Regulatory Momentum - AInvest
Krystal Biotech Exceeds Q2 2025 Earnings Estimates with $96 Million Revenue, $1.33 EPS - AInvest
Krystal Biotech sees revenue growth but anticipates dip due to summer vacations - The Business Journals
Contradictions Unveiled: Krystal Biotech's Q2 2025 Earnings Call Reveals Conflicting Insights on VYJUVEK Sales and Market Strategy - AInvest
Krystal Biotech, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating - TipRanks
Krystal Biotech shares fall 12.71% intraday after missing Q2 earnings estimates. - AInvest
Krystal Biotech Q2 2025 slides: VYJUVEK drives growth amid global expansion - Investing.com Canada
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips - Investing.com Canada
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Transcript : Krystal Biotech, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Krystal Biotech shares jump as Q2 results exceed expectations By Investing.com - Investing.com India
Krystal Biotech shares jump as Q2 results exceed expectations - Investing.com
Krystal Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Krystal Biotech Q2 Earnings, Revenue Rise - MarketScreener
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q2 Revenue $96.0M, vs. FactSet Est of $92.0M - MarketScreener
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results - TradingView
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
Krystal Biotech Inc (KRYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Krishnan Suma | President, R&D |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,389 |
208,350 |
1,508,056 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,435 |
2,019,225 |
1,443,276 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Krish S | President and CEO |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):